"description","label","name","rationale","uuid:ID","id"
"The main design for the study","","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","469dbac0-4a82-4a12-a953-9e0382b402a4","StudyDesign_1"
